Martin Andreas RÃ, der

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2403816/publications.pdf

Version: 2024-02-01

113 papers 4,208 citations

257450 24 h-index 60 g-index

123 all docs

123 docs citations

123 times ranked 7534 citing authors

#	Article	IF	Citations
1	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nature Genetics, 2018, 50, 928-936.	21.4	652
2	Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nature Genetics, 2013, 45, 385-391.	21.4	492
3	A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nature Genetics, 2014, 46, 1103-1109.	21.4	408
4	Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nature Genetics, 2011, 43, 785-791.	21.4	265
5	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nature Genetics, 2021, 53, 65-75.	21.4	264
6	Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. Lancet, The, 2020, 396, 1413-1421.	13.7	226
7	Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. BMJ: British Medical Journal, 2018, 360, j5757.	2.3	153
8	Active surveillance for clinically localized prostate cancer––A systematic review. Journal of Surgical Oncology, 2014, 109, 830-835.	1.7	139
9	A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Human Molecular Genetics, 2013, 22, 408-415.	2.9	118
10	Prostate artery embolisation for benign prostatic hyperplasia: a systematic review and meta-analysis. European Radiology, 2019, 29, 287-298.	4.5	98
11	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nature Communications, 2018, 9, 2256.	12.8	88
12	ERG Protein Expression in Diagnostic Specimens Is Associated with Increased Risk of Progression During Active Surveillance for Prostate Cancer. European Urology, 2014, 66, 851-860.	1.9	75
13	Does Cytoreductive Prostatectomy Really Have an Impact on Prognosis in Prostate Cancer Patients with Low-volume Bone Metastasis? Results from a Prospective Case-Control Study. European Urology Focus, 2017, 3, 646-649.	3.1	72
14	Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate. Scandinavian Journal of Urology, 2014, 48, 268-275.	1.0	59
15	Trends in incidence and 5â€year mortality in men with newly diagnosed, metastatic prostate cancer—A populationâ€based analysis of 2 national cohorts. Cancer, 2018, 124, 2931-2938.	4.1	58
16	Proteogenomic Characterization of Patient-Derived Xenografts Highlights the Role of REST in Neuroendocrine Differentiation of Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2019, 25, 595-608.	7.0	55
17	Risk of prostate cancer diagnosis and mortality in men with a benign initial transrectal ultrasound-guided biopsy set: a population-based study. Lancet Oncology, The, 2017, 18, 221-229.	10.7	54
18	Short-term morbidity and mortality following radical cystectomy: a systematic review. BMJ Open, 2021, 11, e043266.	1.9	48

#	Article	IF	Citations
19	Germline variation at 8q24 and prostate cancer risk in men of European ancestry. Nature Communications, 2018, 9, 4616.	12.8	43
20	Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide. EJNMMI Research, 2016, 6, 23.	2.5	37
21	Active surveillance can reduce overtreatment in patients with low-risk prostate cancer. Danish Medical Journal, 2013, 60, A4575.	0.5	32
22	Serum testosterone level as a predictor of biochemical failure after radical prostatectomy for localized prostate cancer. BJU International, 2012, 109, 520-524.	2.5	31
23	Diagnostic characteristics of lethal prostate cancer. European Journal of Cancer, 2017, 84, 18-26.	2.8	31
24	Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I/II clinical trial., 2020, 8, e001157.		28
25	Danish Prostate Cancer Registry & Danish	3.0	25
26	Palliative Prostate Artery Embolization for Prostate Cancer: A Case Series. CardioVascular and Interventional Radiology, 2019, 42, 1405-1412.	2.0	21
27	Vitamin D levels and the risk of prostate cancer and prostate cancer mortality. Acta Oncol \tilde{A}^3 gica, 2021, 60, 316-322.	1.8	20
28	The impact of the 2005 International Society of Urological Pathology consensus guidelines on Gleason grading – a matchedâ€pair analysis. BJU International, 2016, 117, 883-889.	2.5	19
29	Open vs robotâ€assisted radical cystectomy (BORARC): a doubleâ€blinded, randomised feasibility study. BJU International, 2022, 130, 102-113.	2.5	19
30	Prostate needle biopsies: interobserver variation and clinical consequences of histopathological reâ€evaluation. Apmis, 2011, 119, 239-246.	2.0	18
31	Survival after radical prostatectomy for clinically localised prostate cancer: a populationâ€based study. BJU International, 2014, 113, 541-547.	2.5	18
32	The risk of biochemical recurrence for intermediate-risk prostate cancer after radical prostatectomy. Scandinavian Journal of Urology, 2017, 51, 450-456.	1.0	18
33	Molecular Profiling of Docetaxel-Resistant Prostate Cancer Cells Identifies Multiple Mechanisms of Therapeutic Resistance. Cancers, 2021, 13, 1290.	3.7	17
34	Morbidity and Days Alive and Out of Hospital Within 90 Days Following Radical Cystectomy for Bladder Cancer. European Urology Open Science, 2021, 28, 1-8.	0.4	17
35	Elevated miR-615-3p Expression Predicts Adverse Clinical Outcome and Promotes Proliferation and Migration of Prostate Cancer Cells. American Journal of Pathology, 2019, 189, 2377-2388.	3.8	16
36	Prostate Artery Embolization for Lower Urinary Tract Symptoms in Men Unfit for Surgery. Diagnostics, 2019, 9, 46.	2.6	16

#	Article	IF	Citations
37	Postembolization Syndrome after Prostatic Artery Embolization: A Systematic Review. Diagnostics, 2020, 10, 659.	2.6	16
38	Urokinase-Type Plasminogen Activator Receptor (uPAR) PET/MRI of Prostate Cancer for Noninvasive Evaluation of Aggressiveness: Comparison with Gleason Score in a Prospective Phase 2 Clinical Trial. Journal of Nuclear Medicine, 2021, 62, 354-359.	5.0	16
39	Exercise training to increase tumour natural killerâ€cell infiltration in men with localised prostate cancer: a randomised controlled trial. BJU International, 2023, 131, 116-124.	2.5	16
40	Systematic review: does endocrine therapy prolong survival in patients with prostate cancer?. Scandinavian Journal of Urology, 2016, 50, 135-143.	1.0	15
41	Active surveillance for localized prostate cancer: An analysis of patient contacts and utilization of healthcare resources. Scandinavian Journal of Urology, 2015, 49, 43-50.	1.0	14
42	First Danish Single-Institution Experience with Radical Prostatectomy: Biochemical Outcome in 1200 Consecutive Patients. Prostate Cancer, 2011, 2011, 1-5.	0.6	13
43	Is it possible to predict lowâ€volume and insignificant prostate cancer by core needle biopsies?. Apmis, 2013, 121, 257-265.	2.0	13
44	Anastomotic complications after robot-assisted laparoscopic and open radical prostatectomy. Scandinavian Journal of Urology, 2016, 50, 274-279.	1.0	13
45	Risk of Depression After Radical Prostatectomy—A Nationwide Registry-based Study. European Urology Oncology, 2021, 4, 601-608.	5.4	13
46	The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer. Expert Review of Anticancer Therapy, 2008, 8, 361-369.	2.4	12
47	Predictive value of combined analysis of proâ€≺scp>NPY and <scp>ERG</scp> in localized prostate cancer. Apmis, 2018, 126, 804-813.	2.0	12
48	Active Surveillance Versus Radical Prostatectomy in Favorable-risk Localized Prostate Cancer. Clinical Genitourinary Cancer, 2019, 17, e814-e821.	1.9	12
49	Primary Gleason pattern in biopsy Gleason score 7 is predictive of adverse histopathological features and biochemical failure following radical prostatectomy. Scandinavian Journal of Urology, 2014, 48, 168-176.	1.0	11
50	Prostateâ€specific antigen doubling time as a progression criterion in an active surveillance programme for patients with localized prostate cancer. BJU International, 2014, 113, E98-105.	2.5	11
51	The predictive value of ERG protein expression for development of castration-resistant prostate cancer in hormone-na \tilde{A} ve advanced prostate cancer treated with primary androgen deprivation therapy. Prostate, 2015, 75, 1499-1509.	2.3	11
52	Copenhagen uPAR prostate cancer (CuPCa) database: protocol and early results. Biomarkers in Medicine, 2016, 10, 209-216.	1.4	11
53	Long-Term Renal Function Following Radical Cystectomy for Bladder Cancer. Urology, 2022, 160, 147-153.	1.0	11
54	Changes in preoperative characteristics in patients undergoing radical prostatectomy $\hat{a} \in \hat{a}$ a 16-year nationwide analysis. Acta Oncol \hat{A}^3 gica, 2014, 53, 361-367.	1.8	10

#	Article	IF	CITATIONS
55	A single-center experience with abiraterone as treatment for metastatic castration-resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 291.e1-291.e7.	1.6	10
56	A Nationwide Analysis of Risk of Prostate Cancer Diagnosis and Mortality following an Initial Negative Transrectal Ultrasound Biopsy with Long-Term Followup. Journal of Urology, 2022, 208, 100-108.	0.4	10
57	Risk of biochemical recurrence and positive surgical margins in patients with pT2 prostate cancer undergoing radical prostatectomy. Journal of Surgical Oncology, 2014, 109, 132-138.	1.7	9
58	Risk factors associated with positive surgical margins following radical prostatectomy for clinically localized prostate cancer: Can nerve-sparing surgery increase the risk?. Scandinavian Journal of Urology, 2014, 48, 15-20.	1.0	9
59	Cytoreductive prostatectomy in metastatic prostate cancer: a systematic review. Scandinavian Journal of Urology, 2018, 52, 1-7.	1.0	9
60	Educational level and first-time PSA testing in general practice. Scandinavian Journal of Urology, 2019, 53, 275-281.	1.0	9
61	ERG protein expression over time: from diagnostic biopsies to radical prostatectomy specimens in clinically localised prostate cancer. Journal of Clinical Pathology, 2015, 68, 788-794.	2.0	8
62	Radical prostatectomy in Denmark: Survival analysis and temporal trends in clinicopathological parameters with up to 20 years of follow-up. Surgical Oncology, 2017, 26, 21-27.	1.6	8
63	The prognostic impact of incidental prostate cancer following radical cystoprostatectomy: a nationwide analysis. Scandinavian Journal of Urology, 2018, 52, 358-363.	1.0	8
64	Validation of the four-miRNA biomarker panel MiCaP for prediction of long-term prostate cancer outcome. Scientific Reports, 2020, 10, 10704.	3.3	8
65	Surgical Approaches and Outcomes in Living Donor Nephrectomy: A Systematic Review and Meta-analysis. European Urology Focus, 2022, 8, 1795-1801.	3.1	8
66	Quality of life and secondary outcomes for open versus robot-assisted radical cystectomy: a double-blinded, randomised feasibility trial. World Journal of Urology, 2022, 40, 1669-1677.	2.2	8
67	Itraconazole Reverts ABCB1-Mediated Docetaxel Resistance in Prostate Cancer. Frontiers in Pharmacology, 0, 13, .	3.5	8
68	First danish single-institution experience with radical prostatectomy: impact of surgical margins on biochemical outcome. Scandinavian Journal of Urology and Nephrology, 2012, 46, 172-179.	1.4	7
69	The CPC Risk Calculator: A New App to Predict Prostate-specific Antigen Recurrence During Follow-up After Radical Prostatectomy. European Urology Focus, 2018, 4, 360-368.	3.1	7
70	Risk of depression after diagnostic prostate cancer workup–ÂA nationwide, registryâ€based study. Psycho-Oncology, 2021, 30, 1939-1947.	2.3	7
71	Radical prostatectomy in clinically localized high-risk prostate cancer: Outcome of 231 consecutive patients. Scandinavian Journal of Urology, 2013, 47, 19-25.	1.0	6
72	Nonâ€apical positive surgical margins after radical prostatectomy for pT2 prostate cancer is associated with the highest risk of recurrence. Journal of Surgical Oncology, 2014, 109, 818-822.	1.7	6

#	Article	IF	CITATIONS
73	Selective arterial embolization of renal angiomyolipomas: A 10â€year experience. BJUI Compass, 2022, 3, 86-92.	1.3	5
74	Patients undergoing radical prostatectomy have a better survival than the background population. Danish Medical Journal, 2013, 60, A4612.	0.5	5
75	Temporal Trends in Clinical and Pathological Characteristics for Men Undergoing Radical Prostatectomy Between 1995 and 2013 at Rigshospitalet, Copenhagen, Denmark, and Stanford University Hospital, United States. Clinical Genitourinary Cancer, 2018, 16, e181-e192.	1.9	4
76	5hmC Level Predicts Biochemical Failure Following Radical Prostatectomy in Prostate Cancer Patients with ERG Negative Tumors. International Journal of Molecular Sciences, 2019, 20, 1025.	4.1	4
77	Novel functions of the luteinizing hormone/chorionic gonadotropin receptor in prostate cancer cells and patients. PLoS ONE, 2020, 15, e0238814.	2.5	4
78	Detection of Clinically Significant Prostate Cancer by Systematic TRUS-Biopsies in a Population-Based Setting Over a 20 Year Period. Urology, 2021, 155, 20-25.	1.0	4
79	What is the risk of prostate cancer mortality following negative systematic TRUS-guided biopsies? A systematic review. BMJ Open, 2020, 10, e040965.	1.9	4
80	Center experience and other determinants of patient radiation exposure during prostatic artery embolization: a retrospective study in three Scandinavian centers. European Radiology, 2022, 32, 2404-2413.	4.5	4
81	Safety and oncological outcome following radiofrequency ablation of small renal masses in a single center. Scandinavian Journal of Urology, 2021, 55, 203-208.	1.0	3
82	Risk of recurrence and long-term mortality following radical cystectomy for bladder cancer. Scandinavian Journal of Urology, 2022, 56, 149-154.	1.0	3
83	Length of life gained with surgical treatment of prostate cancer: A population-based analysis. Scandinavian Journal of Urology, 2015, 49, 275-281.	1.0	2
84	The use of transrectal ultrasound-guided biopsy following the introduction of prostate-specific antigen testing in Denmark: a population-based analysis. Scandinavian Journal of Urology, 2018, 52, 169-173.	1.0	2
85	The Association between Plasma Levels of Intact and Cleaved uPAR Levels and the Risk of Biochemical Recurrence after Radical Prostatectomy for Prostate Cancer. Diagnostics, 2020, 10, 877.	2.6	2
86	Prescription rates for commonly used drugs before and after a prostate cancer diagnosis. Cancer Causes and Control, 2022, , $1.$	1.8	2
87	A case of iatrogenic ureteric injury presenting with headache. Nature Reviews Urology, 2008, 5, 113-116.	1.4	1
88	The drama of prostate cancer diagnostics – Authors' reply. Lancet Oncology, The, 2017, 18, e133.	10.7	1
89	Plasma levels of intact and cleaved urokinase plasminogen activator receptor (uPAR) in men with clinically localised prostate cancer. Journal of Clinical Pathology, 2017, 70, 1063-1068.	2.0	1
90	Prognostic implication of gait function following treatment for spinal cord compression in men diagnosed with prostate cancer. Scandinavian Journal of Urology, 2019, 53, 222-228.	1.0	1

#	Article	IF	Citations
91	AZGP1 Protein Expression in Hormone-NaÃ-ve Advanced Prostate Cancer Treated with Primary Androgen Deprivation Therapy. Diagnostics, 2020, 10, 520.	2.6	1
92	Can Computed Tomography Perfusion Predict Treatment Response After Prostate Artery Embolization: A Feasibility Study. Diagnostics, 2020, 10, 304.	2.6	1
93	Efficacy of dexamethasone in reducing the postembolisation syndrome in men undergoing prostatic artery embolisation for benign prostatic hyperplasia: protocol for a single-centre, randomised, double-blind, placebo-controlled trial—the †DEXAPAE' study. BMJ Open, 2021, 11, e047878.	1.9	1
94	Radical prostatectomy for clinically localised prostate cancer at Rigshospitalet 1995-2011 - an analysis of surgical and oncological outcome. Danish Medical Journal, 2013, 60, B4752.	0.5	1
95	Prescription rates for drugs used in treatment of benign prostatic hyperplasia and erectile dysfunction before and after prostate cancer diagnosis. Acta OncolA³gica, 2022, 61, 931-938.	1.8	1
96	Response to: K B Bell, M Kida & K Cooper: Histopathology sampling of radical prostatectomy specimens: representative or entire submission?. Histopathology, 2011, 59, 1014-1014.	2.9	0
97	994 STANDARDIZED RELATIVE SURVIVAL AND MORTALITY AFTER RADICAL PROSTATECTOMY FOR CLINICALLY LOCALIZED PROSTATE CANCER. Journal of Urology, 2013, 189, .	0.4	0
98	996 NATION-WIDE ANALYSIS OF SURVIVAL AFTER RADICAL PROSTATECTOMY FOR CLINICALLY LOCALIZED PROSTATE CANCER IN DENMARK 1995-2011. Journal of Urology, 2013, 189, .	0.4	0
99	PD27-12 BIOCHEMICAL EFFICACY OF ENZALUTAMIDE IN POST-CHEMO MCRPC PATIENTS PREVIOUSLY TREATED WITH ABIRATERONE. Journal of Urology, 2014, 191, .	0.4	0
100	MP70-19 KETOCONAZOLE THERAPY IN POST-CHEMO MCRPC - THE CASE FOR A COMPARISON TO ABIRATERONE. Journal of Urology, 2014, 191, .	0.4	0
101	MP62-20 ESTIMATED LENGTH OF LIFE GAINED WITH RADICAL PROSTATECTOMY COMPARED TO THE BACKGROUND POPULATION: A POPULATION-BASED ANALYSIS. Journal of Urology, 2014, 191, .	0.4	0
102	PD26-01 CHANGES IN CLINICO-PATHOLOGICAL CHARACTERISTICS AT PROSTATE CANCER DIAGNOSIS DETECTED ON PROSTATE BIOPSIES IN DANISH MEN FROM 1995 TO 2011. Journal of Urology, 2016, 195, .	0.4	0
103	The impact of positive surgical margins on salvage radiation or androgen deprivation therapy following radical prostatectomy $\hat{a} \in \hat{a}$ a nationwide study. Acta Oncol \hat{A}^3 gica, 2021, 60, 620-626.	1.8	0
104	Urokinase plasminogen activator receptor (uPAR) as a novel biomarker in prostate cancer Journal of Clinical Oncology, 2015, 33, 183-183.	1.6	0
105	Survival trends in patients diagnosed with metastatic prostate cancer: A nationwide analysis Journal of Clinical Oncology, 2017, 35, 171-171.	1.6	0
106	Nationwide analysis: Changes in the natural history of low risk localized prostate cancer Journal of Clinical Oncology, 2017, 2017, 12-12.	1.6	0
107	Nationwide analysis: Changes in the natural history of low risk localized prostate cancer Journal of Clinical Oncology, 2017, 35, 12-12.	1.6	0
108	Diagnostic characteristics of men harboring lethal prostate cancer: A population-based analysis Journal of Clinical Oncology, 2017, 35, 217-217.	1.6	0

#	Article	IF	CITATIONS
109	Risk of depression following prostate cancer work-up: A nationwide study Journal of Clinical Oncology, 2019, 37, 5061-5061.	1.6	О
110	Antibiotic prophylaxis and complications following prostate biopsies - a systematic review. Danish Medical Journal, 2017, 64, .	0.5	0
111	Reply to Djaladat H and Ghoreifi A's Letter-to-the-Editor Re: Vejlgaard M, Maibom SL, Stroomberg HV, et al. Long-term Renal Function Following Radical Cystectomy for Bladder Cancer. Urology. 2021;S0090-4295(21)01083-9. doi:10.1016/j.urology.2021.11.015. Urology, 2022, , .	1.0	O
112	Reply by Authors. Journal of Urology, 2022, , 101097JU0000000000249103.	0.4	0
113	Prostatic artery embolization in men with severe hemophilia a: a case report of two patients. CVIR Endovascular, 2022, 5, 21.	1.1	0